Economic evaluation of exercise training in patients with pulmonary hypertension

Lung

Volumn 192, Issue 3, 2014, Pages 359-366

  Ehlken, Nicola ^a   Verduyn, Cora ^b   Tiede, Henning ^c   Staehler, Gerd ^d   Karger, Gabriele ^e   Nechwatal, Robert ^e   Opitz, Christian F ^f   Klose, Hans ^g   Wilkens, Heinrike ^g   Rosenkranz, Stephan ^h   Halank, Michael ⁱ   Grünig, Ekkehard ^a  

^a Department of Pneumology Thoraxclinic Heidelberg ^*  (Germany)

^b MAPI GROUP   (Netherlands)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d Clinic Löwenstein   (Germany)

^e Rehabilitation Hospital Heidelberg Königstuhl   (Germany)

^f German Red Cross Hospital   (Germany)

^g UNIVERSITY OF HAMBURG   (Germany)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Cost effectiveness; Exercise training; Pulmonary hypertension; Socioeconomic model; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEATH; ECHOCARDIOGRAPHY; ECONOMIC EVALUATION; ELECTROCARDIOGRAM; EXERCISE; FOLLOW UP; HEALTH CARE COST; HEMODYNAMIC PARAMETERS; HOSPITALIZATION; HUMAN; LABORATORY TEST; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; SHORT FORM 36; SURVIVAL RATE; WALKING; CASE CONTROL STUDY; COST CONTROL; DISEASE COURSE; ECONOMICS; EXERCISE TOLERANCE; FEMALE; HYPERTENSION, PULMONARY; KINESIOTHERAPY; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; COST SAVINGS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MODELS, ECONOMIC; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901261402     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-014-9558-9     Document Type: Article

References (22)

1. Löwe B, Gräfe K, Ufer C, Kroenke K, Grünig E, Herzog W, Borst MM (2004) Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 66:831-836 (Pubitemid 39552865)
2. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34:1219-1263
3. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, Grunig E, Staehler G, Rosenkranz S, Halank M, Held M, Grohé C, Lange TJ, Behr J, Klose H, Wilkens H, Filusch A, Germann M, Ewert R, Seyfarth HJ, Olsson KM, Opitz CF, Gaine SP, Vizza CD, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Pittrow D (2012) Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 68(2):871-880. doi:10.1016/j.ijcard.2012.10.026
4. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, Welte T, Hoeper MM (2012) The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 39:589-596
5. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138:1383-1394
6. Wilkens H, Grimminger F, Hoeper M, Stähler G, Ehlken B, Plesnila-Frank C, Berger K, Resch A, Ghofrani A (2010) Burden of pulmonary arterial hypertension in Germany. Respir Med 104:902-910
7. Reed SD, Whellan DJ, Li Y, Friedman JY, Ellis SJ, Piña IL, Settles SJ, Davidson-Ray L, Johnson JL, Cooper LS, O'Connor CM, Schulman KA, HF-ACTION Investigators (2010) Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes 3:374-381
8. Halank M, Einsle F, Lehman S, Bremer H, Ewert R, Wilkens H, Meyer FJ, Grünig E, Seyfarth H-J, Kolditz M, Wieder G, Höffken G, Köllner V (2013) Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung 91(4):337-343. doi:10.1007/s00408-013-9472-6
9. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E (2006) Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114:1482-1489 (Pubitemid 44527003)
10. Grünig E, Ehlken N, Ghofrani A, Staehler G, Meyer FJ, Juenger J, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Olschewski H, Halank M (2011) Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration 81:394-401
11. Grünig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Staehler G, Halank M, Fischer C, Seyfarth HJ, Klose H, Meyer A, Sorichter S, Wilkens H, Rosenkranz S, Opitz C, Leuchte H, Karger G, Speich R, Nagel C (2012) Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J 40:84-92
12. Becker-Grünig T, Klose H, Ehlken N, Lichtblau M, Nagel C, Fischer C, Gorenflo M, Tiede H, Schranz D, Hager A, Kaemmerer H, Miera O, Ulrich S, Speich R, Uiker S, Grünig E (2012) Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol 168(1):375-381. doi:10.1016/j.ijcard.2012.09.036
13. Wensel R, Opitz CF, Anker SD, Winkler J, Höffken G, Kleber FX, Sharma R, Hummel M, Hetzer R, Ewert R (2002) Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106:319-324 (Pubitemid 34778955)
14. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K (2000) Clinical correlates and prognostic significance of 6-min walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487-492 (Pubitemid 30129457)
15. Weinstein MC, Stason WB (1976) Hypertension: a policy perspective. Harvard University Press, Cambridge, MA
16. Klarman H, Francis J, Rosenthal G (1968) Cost-effectiveness analysis applied to the treatment of chronic renal disease. Med Care 6:48-54
17. Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D (2009) Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess 13:1-320
18. Angalakuditi M, Edgell E, Beardsworth A, Buysman E, Bancroft T (2010) Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ 13:393-402
19. Kühr EM, Ribeiro RA, Rohde LE, Polanczyk CA (2011) Cost-effectiveness of supervised exercise therapy in heart failure patients. Value Health 14:S100-S107
20. Georgiou D, Chen Y, Appadoo S, Belardinelli R, Greene R, Parides MK, Glied S (2001) Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. Am J Cardiol 87(984-988):A4
21. Sohn S, Helms TM, Pelleter JT, Müller A, Kröttinger AI, Schöffski O (2012) Costs and benefits of personalized healthcare for patients with chronic heart failure in the care and education program "Telemedicine for the Heart.". Telemed J E Health 18:198-204
22. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J (2005) Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26:858-863 (Pubitemid 41632043)